<DOC>
	<DOCNO>NCT01748812</DOCNO>
	<brief_summary>Background : - Hypophosphatemia condition person low level phosphorus blood . Low blood phosphorus cause muscle bone weakness ( rickets ) teeth problem . One cause condition much fibroblast growth factor 23 ( FGF23 ) . FGF23 hormone cause kidney get rid phosphorus urine . It also prevent body make vitamin D , help body absorb phosphorus food . - Many people low blood phosphorus take high dos phosphorus calcium medication . However , one side effect drug increase blood level parathyroid hormone ( PTH ) . The drug cinacalcet help lower PTH level , may decrease amount phosphorus lose urine increase phosphorus level blood . Researchers want see cinacalcet help blood phosphorus decrease amount phosphorus supplement people need take . Objectives : - To see cinacalcet safe effective treatment people low phosphorus condition due high FGF23 . Eligibility : - Individuals 18 70 year age different form hypophosphatemic rickets tumor-induced hypophosphatemia Design : - Participants 25 study visit 28 week . - Participants screen physical exam medical history . Blood urine sample collect . - Up three lab visit blood urine test require treatment . Imaging study bone , spine , kidney perform . - Participants 3-night hospital stay start treatment . They take cinacalcet day . Treatment monitor frequent blood test image study . - Participants continue take cinacalcet day 3 week . They regular study visit monitor treatment . - There two overnight hospital stay ( 1 3 night ) adjust cinacalcet dos . The dose increase maximum dose reach , side effect develop . - After end cinacalcet study , participant several followup visit monitor effect treatment .</brief_summary>
	<brief_title>Cinacalcet Fibroblast Growth Factor 23 ( FGF23 ) -Mediated Hypophosphatemia ( Hypophosphatemic Rickets )</brief_title>
	<detailed_description>OBJECTIVES : The primary objective protocol evaluate tolerability cinacalcet individual fibroblast growth factor 23 ( FGF23 ) -mediated hypophosphatemia , use open-label , dose-titration study once-daily dose . Secondary objective evaluate pharmacodynamics cinacalcet subject population explore efficacy cinacalcet compare ) level oral phosphate require baseline level require maximum tolerate dose ( MTD ) b ) change renal phosphate handle baseline MTD . Tertiary objective evaluate tolerability , pharmacodynamics , efficacy twice daily dose subject MTD cinacalcet completion once-daily dose-titration phase . A final objective determine length time take subject return pre-treatment steady state treatment complete . STUDY POPULATION : Up 17 subject FGF23-mediated hypophosphatemia treat . DESIGN : This study open-label , dose-titration study once-daily dose cinacalcet , 4 escalating dos give approximately 3 week interval . After initial standard care optimization period 2-9 week , subject proceed cinacalcet dose-titration period . Subjects experience extend toxicity study drug relate serious adverse event relate , intolerable adverse event titrate low dose study medication . After subject achieve maximum tolerate dose ( MTD ) complete once-daily dosing phase , continue study medication approximately 3 additional week twice daily dose MTD . At end cinacalcet treatment phase study , cinacalcet discontinue standard care ( SOC ) medication adjusted/restarted individualized basis . Subjects continue final SOC safety follow-up period 4 week SOC medication re-equilibrated . OUTCOME MEASURES : Primary safety : Whether subject discontinue study due toxicity , relate serious adverse event ( SAE ) , relate intolerable adverse event ( AE ) . Secondary safety : - &lt; TAB &gt; Maximum tolerate dose cinacalcet - &lt; TAB &gt; Serum calcium level - &lt; TAB &gt; Urine calcium level - &lt; TAB &gt; Adverse event - &lt; TAB &gt; Time cinacalcet discontinuation return pre-treatment standard care dosage level Secondary efficacy : - &lt; TAB &gt; Pharmacodynamic assessment - &lt; TAB &gt; Serum : FGF23 , intact parathyroid hormone , calcium , creatinine , phosphorus - &lt; TAB &gt; Urine : phosphorus , creatinine , calcium . - &lt; TAB &gt; Tubular maximum reabsorption phosphate/glomerular filtration rate - &lt; TAB &gt; Tubular reabsorption phosphate - &lt; TAB &gt; Other - &lt; TAB &gt; Change oral phosphate calcitriol intake require maintain adequate phosphorus calcium serum level - &lt; TAB &gt; Serum osteocalcin alkaline phosphatase - &lt; TAB &gt; Serum intact parathyroid hormone ( PTH ) Tertiary efficacy : - &lt; TAB &gt; Twice-Daily Dosing MTD - &lt; TAB &gt; Time cinacalcet discontinuation twice-daily dose return pre-treatment standard care dosage level - &lt; TAB &gt; Dental Evaluation - &lt; TAB &gt; Visible Plaque Index ( VPI ) - &lt; TAB &gt; Gingival Bleeding Index ( GBI ) - &lt; TAB &gt; Position Gingival Margin ( PGM ) - &lt; TAB &gt; Relative Attachment Level ( RAL ) - &lt; TAB &gt; Periodontal Probing Pocket Depth ( PPD ) - &lt; TAB &gt; Gingival Crevicular Fluid ( GCF ) Biomarkers</detailed_description>
	<mesh_term>Hypophosphatemia</mesh_term>
	<mesh_term>Osteomalacia</mesh_term>
	<mesh_term>Rickets , Hypophosphatemic</mesh_term>
	<mesh_term>Familial Hypophosphatemic Rickets</mesh_term>
	<mesh_term>Cinacalcet Hydrochloride</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>INCLUSION CRITERIA : 1 . &lt; TAB &gt; Chronological age : 1870 year 2 . &lt; TAB &gt; Diagnosis genetic form FGF23mediated hypophosphatemia : 1 . &lt; TAB &gt; Xlinked hypophosphatemic rickets ( XLH ) 2 . &lt; TAB &gt; Autosomal dominant hypophosphatemic rickets ( ADHR ) 3 . &lt; TAB &gt; Autosomal recessive hypophosphatemic rickets ( ARHR ) Or , diagnosis nongenetic form FGF23mediated hypophosphatemia , i.e . tumorinduced osteomalacia ( TIO ) 3 . &lt; TAB &gt; Ability understand provide inform consent 4 . &lt; TAB &gt; Ability complete protocol schedule assessment medication regimen 5 . &lt; TAB &gt; Women childbearing potential ( surgically sterile via tubal ligation , bilateral oophorectomy hysterectomy , postmenopausal great equal 1 year ) must agree practice adequate contraception may include , limited , abstinence , monogamous relationship vasectomize partner , barrier method condom , diaphragm , spermicide , intrauterine device , license hormonal method duration treatment portion study . EXCLUSION CRITERIA : 1 . &lt; TAB &gt; Chronic recurrent hypocalcemia define serum calcium &lt; 8.4 mg/dL ( 2.1 mmol/L ) 2 . &lt; TAB &gt; Tertiary hyperparathyroidism evidence concurrent PTH calcium level upper limit normal 3 . &lt; TAB &gt; History parathyroid surgery and/or hypoparathyroidism 4 . &lt; TAB &gt; Hypercalciuria define &gt; 4 mg/kg/day ( 0.1 mmol/kg/day ) optimize conventional therapy ( determine SOC optimization phase ) 5 . &lt; TAB &gt; Moderate severe hepatic insufficiency define total bilirubin &gt; 2 mg/dL serum albumin &lt; 3 g/dL International Normalized Ratio ( INR ) &gt; 2 OR presence ascites hepatic encephalopathy . 6 . &lt; TAB &gt; A calculated eGFR &lt; 50 mL/min/1.73 ( 2 ) , use CKDEPI equation 7 . &lt; TAB &gt; History nonfebrile seizure disorder 8 . &lt; TAB &gt; History clinically significant cardiac arrhythmia 9 . &lt; TAB &gt; History chronic gastrointestinal disease 10 . &lt; TAB &gt; Current therapy ( time inform consent ) bisphosphonates , calcitonin , diuretic medication may significant drug interaction cinacalcet 11 . &lt; TAB &gt; Known hypersensitivity cinacalcet constituent 12 . &lt; TAB &gt; Positive pregnancy test lactation 13 . &lt; TAB &gt; Use another investigational agent ( i.e. , context clinical trial , use investigational product may impact study ) within last 3 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Tumor Induced Osteomalacia</keyword>
	<keyword>Hypophosphatemic Rickets</keyword>
</DOC>